

**FORM 51-102F3  
MATERIAL CHANGE REPORT**

**Item 1. Name and Address of Company**

Abattis Bioceticals Corp.  
1000 - 355 Burrard Street  
Vancouver, BC V6C 2G8

**Item 2. Date of Material Change**

March 10, 2014

**Item 3. News Release**

A news release dated and disseminated March 10, 2014 at Vancouver, British Columbia, through The Newswire.ca, CSE Markets and SEDAR is attached as Schedule "A".

**Item 4. Summary of Material Change**

Abattis announced the grant of 330,000 incentive stock options.

**Item 5. Full Description of Material Change**

See news release, a copy of which is attached hereto.

**Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**Item 7. Omitted Information**

Not applicable.

**Item 8. Executive Officer**

Mike Withrow  
Telephone: 778 896 6536

**Item 9. Date of Report**

March 10, 2014

Suite 1000 – 355 Burrard Street  
Vancouver, BC V6C 2G8  
Tel: 778-896-6536  
Info@abattis.com



## ABATTIS ANNOUNCES GRANT OF OPTION

**Vancouver, BC – March 10, 2014 - Abattis Bioceuticals Corp.** (the “Company” or “Abattis”) (OTC PINK: ATTFB) (CSE: ATT) wishes to announce that it has granted incentive stock options to a consultant of the Company to purchase up to 330,000 common shares of the Company. The options are exercisable on or before March 10, 2019, at an exercise price of \$0.80 per share.

### **About Abattis Bioceuticals Corp.**

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. We follow strict Standard Operating Protocols and adhere to the Law's of Canada and Foreign Jurisdictions. For more information, visit the Company's website at [www.abattis.com](http://www.abattis.com).

For further information, contact the Company's CEO, Michael Withrow at (778) 896-6536 or at [mike.withrow@abattis.com](mailto:mike.withrow@abattis.com).

ON BEHALF OF THE BOARD

*“Michael Withrow”*  
President & CEO

***NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.***

### **FORWARD LOOKING INFORMATION**

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis filed under the Company's profile on [www.sedar.com](http://www.sedar.com). While the Company may elect to, it does not undertake to update this information at any particular time.